On Day 1, patients treated with FOLFIRI therapy received a 2-hour intravenous infusion of CPT-11 (150 mg/m2) combined with 1-LV (200 mg/m2), followed by a rapid intravenous infusion of 5-FU (400 mg/m2
Sponsors
NPO Epidemiological and Clinical Research Information Network
Conditions
colorectal cancer
Phase 2
A multicenter phase II study of FOLFIRI as first-line chemotherapy for metastatic colorectal cancer with reduced starting dose of irinotecan in patients with homozygous for UGT1A1(FLIGHT1)
Active, not recruitingJPRN-UMIN000002388
Start: 2005-11-01Target: 50Updated: 2026-06-29
A multicenter phaseII study of FOLFIRI as FOLFOX refractory second-line chemotherapy for metastatic colorectal cancer with reduced starting dose of irinotecan in patients with honozygous for UGT1A1: (FLIGHT2)
Active, not recruitingJPRN-UMIN000002476
Start: 2006-01-01Target: 50Updated: 2026-06-29